Cargando…
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) in Belgium. This interim analysis reports results for patients with CLL,...
Autores principales: | Janssens, Ann, Berneman, Zwi N., Offner, Fritz, Snauwaert, Sylvia, Mineur, Philippe, Vanstraelen, Gaetan, Meers, Stef, Spoormans, Isabelle, Bron, Dominique, Vande Broek, Isabelle, Van Bogaert, Charlotte, De Beleyr, Birgit, Smet, Ann, Nielsen, Lasse, Wapenaar, Robert, André, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763520/ https://www.ncbi.nlm.nih.gov/pubmed/36227519 http://dx.doi.org/10.1007/s44228-022-00020-8 |
Ejemplares similares
-
Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019) -
Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020) -
Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021) -
A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
por: Karvaly, Gellért Balázs, et al.
Publicado: (2022) -
Inhibition of effector B cells by ibrutinib in systemic sclerosis
por: Einhaus, Jakob, et al.
Publicado: (2020)